Retatrutide is an investigational injectable medication currently being evaluated in clinical trials for the treatment of obesity and type 2 diabetes
Patients may experience nausea, vomiting, diarrhea, constipation, stomach pain, reduced appetite, fatigue, or other concerns
Active GLP-1 Forms Generated by the Gut and Brain In the gut and brain, proglucagon is then further processed into various proglucagon peptides, including active GLP-1 8,9
This is mainly due to the rapid weight loss or hormonal imbalance which alters ovulation and hence the menstrual cycle
This allows patients to receive comprehensive information about the effectiveness of these medications, as well as advice about possible side effects
In my experience looking at the trial data, participants on higher doses were losing roughly one to two pounds per week consistently through this phase